Drug intelligence / Profile preview

docetaxel + sunitinib

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of docetaxel, a taxane chemotherapy agent that disrupts the microtubule network essential for mitotic and interphase cellular functions, leading to cell death, and sunitinib, an oral multi-targeted tyrosine kinase inhibitor that works by inhibiting multiple receptor tyrosine kinases involved in tumor growth, pathologic angiogenesis, and metastatic progression. When combined, these agents have shown enhanced antitumor activity in preclinical models compared to single agents.

Targets

ABC family (ATP-binding cassette transporter family)PDGFR (PDGFR family)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on docetaxel + sunitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + sunitinib.

Explore the full profile